Drug Trial Radar · NCT00132938
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Last checked: Nov 19, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,660
Actual
Start
Jan 2004
Primary completion
May 2006
Study completion May 2006
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit 1). Secondary Objectives: The secondary objectives of the study are: * To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit in patients with Sp detected in sputum specimen at the start of the study (Visit 1); * To compare the clinical cure rates achieved by each treatment group in the penicillin or erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp (SSp) population at the End of Therapy (EOT) and Test of Cure visits; * To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of Therapy visit on the presence of Streptococcus pneumoniae strains resistant to beta-lactams or macrolides in the sputum of patients with Sp detected at the start of the study (Visit 1); * To compare the clinical efficacy at the End of Therapy visit and safety at the Test of Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global" randomized population.
Conditions
- Chronic Bronchitis
Interventions
telithromycinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of PERSp in sputum of patients at the TOC visit in each treatment group and who were Sp positive in sputum at Visit 1.
Locations
8 sites in 8 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
Bridgewater, New Jersey
Sanofi-Aventis
Brussels, Belgium
Sanofi-Aventis
Paris, France
Sanofi-Aventis
Budapest, Hungary
Sanofi-Aventis
Casablanca, Morocco
Sanofi-Aventis
Barcelona, Spain
Sanofi-Aventis
Mégrine, Tunisia
Sanofi-Aventis
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.